🔎 Trials Near Me

Beranda › Tumor Neuroendokrin › Kentucky

Uji klinis Tumor Neuroendokrin di Kentucky

7 studi untuk Tumor Neuroendokrin mencari peserta di lokasi di Kentucky.

Kota di Kentucky

Teks studi resmi (Bahasa Inggris)

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  • University of Kentucky Markey Cancer Center, Lexington
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT06943755

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

  • University of Kentucky Medical Center, Lexington
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07087054

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

  • Research Facility, Lexington
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07165132

Project: Every Child for Younger Patients With Cancer

  • University of Kentucky/Markey Cancer Center, Lexington
  • Norton Children's Hospital, Louisville
Menerima pesertaStudi observasional
Hingga usia 25 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT02402244

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

  • Crinetics Study Site, Lexington
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT07129252

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

  • University of Kentucky, Lexington
Menerima pesertaFase 1/2
Usia 18 hingga 90 · Semua jenis kelamin · Diperbarui 14 Mei 2026 · NCT05636618

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

  • Research Facility, Lexington
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Mar 2026 · NCT05477576

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.